Yahoo
XETRA - Delayed Quote EUR

SCHOTT Pharma AG & Co. KGaA (1SXP.DE)

25.45 -0.05 (-0.20%)
As of 1:51:13 PM GMT+2. Market Open.
Chart Range Bar
Loading chart for 1SXP.DE
  • Previous Close 25.50
  • Open 25.50
  • Bid 25.45 x --
  • Ask 25.50 x --
  • Day's Range 25.10 - 25.60
  • 52 Week Range 12.62 - 26.05
  • Volume 18,608
  • Avg. Volume 67,885
  • Market Cap (intraday) 3.833B
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) 28.28
  • EPS (TTM) 0.90
  • Earnings Date Aug 12, 2026
  • Forward Dividend & Yield 0.18 (0.71%)
  • Ex-Dividend Date Feb 4, 2026
  • 1y Target Est 24.92

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

www.schott-pharma.com

5,002

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 10/20/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

1SXP.DE
70.67%
DAX P (^GDAXI)
2.59%

1-Year Return

1SXP.DE
26.95%
DAX P (^GDAXI)
3.57%

3-Year Return

1SXP.DE
13.28%
DAX P (^GDAXI)
69.78%

5-Year Return

1SXP.DE
15.17%
DAX P (^GDAXI)
61.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 281.76M
Earnings 38.83M
Profit Margin 13.78%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
200M
250M
13.0%
13.5%

Analyst Insights

View More

Analyst Price Targets

17.30 Low
24.92 Average
25.45 Current
27.10 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    3.58B

  • Enterprise Value

    3.64B

  • Trailing P/E

    26.44

  • Forward P/E

    21.64

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.53

  • Price/Book (mrq)

    3.60

  • Enterprise Value/Revenue

    3.58

  • Enterprise Value/EBITDA

    13.01

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.40%

  • Return on Assets (ttm)

    6.49%

  • Return on Equity (ttm)

    14.68%

  • Revenue (ttm)

    1.02B

  • Net Income Avi to Common (ttm)

    136.22M

  • Diluted EPS (ttm)

    0.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    24.88M

  • Total Debt/Equity (mrq)

    30.88%

  • Levered Free Cash Flow (ttm)

    -19.74M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: